Connor Clark & Lunn Investment Management Ltd. Has $1.35 Million Position in Axovant Sciences Ltd (AXON)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Axovant Sciences Ltd (NASDAQ:AXON) by 12.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 559,602 shares of the biotechnology company’s stock after acquiring an additional 64,152 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.46% of Axovant Sciences worth $1,354,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Paloma Partners Management Co acquired a new stake in shares of Axovant Sciences during the second quarter valued at $356,000. Tower Research Capital LLC TRC boosted its stake in shares of Axovant Sciences by 1,627.0% during the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 58,541 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Axovant Sciences during the second quarter valued at $338,000. Finally, BlackRock Inc. boosted its stake in shares of Axovant Sciences by 13.5% during the third quarter. BlackRock Inc. now owns 1,424,710 shares of the biotechnology company’s stock valued at $3,447,000 after acquiring an additional 169,918 shares during the last quarter. 7.71% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently commented on AXON shares. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Tuesday, October 9th. BidaskClub raised Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 16th. Cowen reaffirmed a “hold” rating on shares of Axovant Sciences in a research note on Thursday, September 20th. ValuEngine raised Axovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $4.56.

NASDAQ AXON opened at $1.71 on Friday. Axovant Sciences Ltd has a twelve month low of $1.02 and a twelve month high of $6.59. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 1.68.

WARNING: This report was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/12/08/connor-clark-lunn-investment-management-ltd-has-1-35-million-position-in-axovant-sciences-ltd-axon.html.

Axovant Sciences Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Recommended Story: How Do You Calculate Return on Investment (ROI)?

Institutional Ownership by Quarter for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply